Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by Oden6570on Jan 27, 2024 8:24am

231 Views

Post# 35848398

Biopharma M&A outlook for 2024

M&A deal activity in 2023 also highlighted a significant decline in acquirers’ risk appetite compared to previous years, with 74% of transactions focused on de-risked targets with assets which were at least in phase 3 or already on the market, an increase of 16% compared to the average share of 58% for such deals during the four-year period from 2019 to 2022 (see Figure 2).

Biopharma M&A outlook for 2024 - IQVIA

<< Previous

Bullboard Posts

Next >>

Arctic Wolf to acquire BlackBerry’s Cylance endpoint security assets